ReproCELL Incorporated
Notice of Completion of Payment for the Issuance of New Shares and the 20th Stock Acquisition Rights by Third-Party Allotment under the Share and Stock Acquisition Right Issuance Program Agreement, and Withdrawal of Registration for Issuance
As the fourth third-party allotment under the Equity Program, 2,932,000 ordinary shares were issued with payment completed. Additionally, 29,320 stock acquisition rights were issued; the exercise period is 2026/10/21–2030/10/18. The total funds to be raised from the shares and stock acquisition rights exceed 1,960 million yen. The registration for issuance has been withdrawn.
Key Figures
- 2,932,000 shares: Number of ordinary shares issued
- 119 yen: Issue price (ordinary shares)
- 174,454,000 yen: Amount of capital increase
- 29,320 cases: Number of stock acquisition rights issued
- 159 yen: Exercise price (stock acquisition rights)
AI要約
Overview of Capital Policy
Under the Equity Program Agreement with CVI Investments, Inc., the Company issued 2,932,000 ordinary shares as the fourth third-party allotment at an issue price of 119 yen, and the total proceeds amounted to 348,908,000 yen. In addition, 29,320 stock acquisition rights were issued with an exercise period from 2026/10/21 to 2030/10/18 and an exercise price of 159 yen. This is expected to increase capital stock by 174,454,000 yen and capital surplus by 174,454,000 yen. After completion of payment, the registration for issuance has been withdrawn.
Future Impact and Information
This third-party allotment and issuance of stock acquisition rights are part of the capital policy, aiming to strengthen the capital structure through fundraising and an increase in potential shares. The total amount of capital raised may change depending on the exercise of the stock acquisition rights, and actual funds received will depend on exercise outcomes. The withdrawn registration for issuance indicates that the offering was completed. Continued attention is required for future disclosures and developments in applicable conditions.
ReproCELL Incorporated
Company overview · Stock price · Financial data · All IR